{"ticker": {"uuid": "5afed2f2-4133-4878-9cbb-25e7a6e9c649", "symbol": "NBTX", "name": "Nanobiotix", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Nanobiotix Shares Soar Nearly 5%, Targeting Resistance at \u20ac36.20", "summary": "Nanobiotix shares gained almost 5%, reaching \u20ac32.76, making it one of the strongest performers in the SBF 120. This rebound follows a week of consolidation, pushing the stock closer to its MM20 moving average. The company's annual performance remains exceptionally strong, with a ", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-soar-nearly-5-targeting-resistance-at-eur36-20/22844.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-21T09:40:49", "published_display": "21 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Soar by 4.5%, Leading the SBF 120", "summary": "Nanobiotix shares gained 4.25% to \u20ac34.36, leading the SBF 120 and moving above its short-term moving averages. The company's annual performance remains strong, driven by clinical advancements of its candidate JNJ-1900 (NBTXR3) and encouraging phase 2 results. The stock's current ", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-soar-by-4-5-leading-the-sbf-120/22797.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-20T12:39:18", "published_display": "20 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nanobiotix Shares Drop Nearly 3% Yet Maintain an Annual Gain of 692%", "summary": "Nanobiotix stock experienced a nearly 3% drop on Wednesday, placing it among the biggest declines in the SBF 120 index. This downturn is attributed to profit-taking following strong gains, despite the company still boasting an impressive annual performance of nearly 692%. The sto", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-drop-nearly-3-yet-maintain-an-annual-gain-of-692/22652.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-15T12:15:00", "published_display": "15 Jul 2026 12:15", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nanobiotix SA \u2013 EURONEXT:NANO", "summary": "The article provides a financial overview of Nanobiotix SA (EURONEXT: NANO), specifically focusing on its forward price-to-sales ratio. It indicates that the market is closed, and there are no current trades for the stock, with the content being a snapshot from TradingView's fina", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T00:12:52", "published_display": "15 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nanobiotix S.A. Stock 12\u2011Month Price Target Raised to $54.34, Implies 40% Upside", "summary": "Nanobiotix S.A. (NANO) has seen its average 12-month price target raised to $54.34 by 8 analysts, up from $52.3, suggesting a 40% potential upside from its Jul. 9 closing price. The consensus rating among 9 analysts remains a \"Buy,\" with 8 recommending Buy and 1 recommending Hold", "url": "https://www.tradingview.com/news/tradingview:df5c7bff01086:0-nanobiotix-s-a-stock-12-month-price-target-raised-to-54-34-implies-40-upside/", "source_name": "TradingView", "published_at": "2026-07-10T13:39:53", "published_display": "10 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Nanobiotix SA \u2013 EURONEXT:NANO", "summary": "The article provides financial information for Nanobiotix SA (Euronext: NANO), specifically focusing on its enterprise value to EBIT forward. It indicates basic financial data for the company on the TradingView platform, noting that the market was closed at the time of publicatio", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T09:40:50", "published_display": "10 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Soar Over 5%, Landing on the SBF 120 Podium", "summary": "Nanobiotix shares surged over 5% in early trading, propelled by a \"buy\" rating and a \u20ac56 target price from Portzamparc, representing a potential upside of over 55%. The biotech stock broke through its resistance at \u20ac35.18, signaling a bullish resumption, and has seen a 668% gain ", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-soar-over-5-landing-on-the-sbf-120-podium/22502.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-10T09:39:53", "published_display": "10 Jul 2026 09:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nanobiotix SA \u2013 MUN:5NR", "summary": "This article provides financial information for Nanobiotix SA (MUN:5NR), specifically focusing on its price-to-sales forward metric. It appears to be a stub or a data point from a financial platform like TradingView, with no further detailed analysis provided. The content highlig", "url": "https://www.tradingview.com/symbols/MUN-5NR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T03:39:23", "published_display": "10 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Confirm Their Rebound with a +625% Yearly Increase", "summary": "Nanobiotix shares have confirmed their rebound, showing a +625% increase over the past year. The French biotech company's stock is up 2.03% to \u20ac34.10, trading above its short-term moving averages and indicating continued bullish momentum with an RSI of 57. This growth is supporte", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-confirm-their-rebound-with-a-625-yearly-increase/22463.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-09T15:11:12", "published_display": "09 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Nanobiotix S.A. (NBTX)", "summary": "This article examines the historical performance of Nanobiotix S.A. (NBTX) stock, illustrating how a $1,000 investment would have grown over various periods. It details the company's focus on physics-based therapeutic approaches, particularly its oncology product candidate JNJ-19", "url": "https://www.stocktitan.net/tools/stock-return-calculator/NBTX", "source_name": "Stock Titan", "published_at": "2026-07-04T05:09:27", "published_display": "04 Jul 2026 05:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NBTX - Nanobiotix ADR Dividends", "summary": "This article provides detailed financial data and performance metrics for Nanobiotix ADR (NBTX). It covers key financial figures such as market cap, income, sales, and various ratios, along with stock performance over different periods. The data indicates strong past performance ", "url": "https://finviz.com/stock?t=NBTX&ty=dv&ta=1&p=d", "source_name": "Finviz", "published_at": "2026-07-04T01:39:50", "published_display": "04 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Soar 5% and Aim for Record Highs", "summary": "Nanobiotix shares have surged by 5% and are targeting new record highs, becoming a top performer on the Paris index after a period of consolidation. The company's strong performance is supported by technical indicators, significant advances in clinical studies for JNJ-1900, the s", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-soar-5-and-aim-for-record-highs/22051.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-03T17:43:00", "published_display": "03 Jul 2026 17:43", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Up 3.73%, Targeting the 50-Day Moving Average of \u20ac32.70", "summary": "Nanobiotix shares have risen by 3.73% to \u20ac32.28, nearing their 50-day moving average of \u20ac32.70. This rebound follows a period of consolidation after an annual rally, positioning the stock among the top performers on the SBF 120. Despite a recent increase in bearish pressure, the ", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-up-3-73-targeting-the-50-day-moving-average-of-eur32-70/21780.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-30T10:10:04", "published_display": "30 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Decline by 1.5% and Remain Under Pressure Following May Record", "summary": "Nanobiotix shares have fallen by 1.5% and continue to face pressure in a declining Parisian market, consolidating after hitting a record high in mid-May. The stock is currently trading near its 20-day moving average, with bearish bets increasing, although the total short position", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-decline-by-1-5-and-remain-under-pressure-following-may-record/21722.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-29T12:41:20", "published_display": "29 Jun 2026 12:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Nanobiotix SA \u2013 EURONEXT:NANO", "summary": "This article provides access to the enterprise value to EBITDA forward for Nanobiotix SA (EURONEXT:NANO). It primarily functions as a financial data page on TradingView, indicating that specific financial metrics for the company are available for users to view. The content points", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:09:56", "published_display": "27 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Nanobiotix SA \u2013 AQUISEU:NANOP", "summary": "This article provides financial data for Nanobiotix SA (NANOP), specifically its enterprise value to EBITDA forward. It details that the market for this stock is currently closed with no trades recorded. The information is presented by TradingView, sourcing data from ICE Data Ser", "url": "https://www.tradingview.com/symbols/AQUISEU-NANOP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:33", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NANO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an in-depth analysis of Nanobiotix SA (NANO) stock, including its current price, analyst forecasts, historical performance, and financial data. It highlights the company's recent stock increase over the last year, future earnings and revenue expectations, an", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T01:06:36", "published_display": "27 Jun 2026 01:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Nanobiotix SA \u2013 EURONEXT:NANO", "summary": "The article focuses on financial data for Nanobiotix SA (NANO) on Euronext, specifically its \"Price to earnings forward\" metric. It appears to be a financial data page from TradingView, providing an overview of the company's financial performance, news, and community discussions.", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:05:36", "published_display": "27 Jun 2026 01:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NBTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target and analyst ratings for Nanobiotix S.A. (NBTX) for 2027. Nine analysts offer a 1-year price forecast with an average target of 49.59, though maximum and minimum estimates are not provided. The content also notes that 10 analysts have given sto", "url": "https://www.tradingview.com/symbols/BOATS-NBTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:36", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Nanobiotix SA \u2013 EURONEXT:NANO", "summary": "This article displays the \"Price to book forward\" financial metric for Nanobiotix SA (Euronext: NANO) as found on TradingView. It indicates that no trades were recorded and the market was closed at the time of access. The data is provided by ICE Data Services and FactSet, with SE", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:10:09", "published_display": "26 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Fall by 2.5%, in the Red on the SBF 120", "summary": "Nanobiotix shares have fallen by 2.5% on the SBF 120, extending a consolidation phase due to renewed risk aversion from U.S. inflation figures. Despite a monthly decline of over 20%, the stock's annual performance remains strong, boasting over 640% growth. The biotech is also aff", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-fall-by-2-5-in-the-red-on-the-sbf-120/21618.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-26T10:38:09", "published_display": "26 Jun 2026 10:38", "sentiment": "negative", "sentiment_pct": 29, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix SA Actuals & Estimates (EURONEXT:NANO)", "summary": "This article provides an overview of Nanobiotix SA (NANO) stock, including its current price, performance trends, and analyst forecasts. It details financial actuals and estimates for income, balance sheet, and cash flow, alongside key metrics like market capitalization, EBITDA, ", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:09:36", "published_display": "25 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Nanobiotix SA \u2013 GETTEX:5NR", "summary": "This article provides financial information for Nanobiotix SA (GETTEX:5NR), specifically focusing on its price to book forward metric. It appears to be a financial data snippet from TradingView, offering a quick look at the company's valuation under the \"Financials\" section. The ", "url": "https://www.tradingview.com/symbols/GETTEX-5NR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T15:09:36", "published_display": "25 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Fall by 2.5%, Down Nearly 19% Over the Month", "summary": "Nanobiotix shares have fallen by 2.5% today and nearly 19% over the past month, trading at \u20ac29.50. This decline occurs despite a positive trend in the broader Parisian market and successful progress in the company's clinical trials and cash reserve reinforcement. The stock's perf", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-fall-by-2-5-down-nearly-19-over-the-month/21551.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-25T09:40:54", "published_display": "25 Jun 2026 09:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nanobiotix SA \u2013 GETTEX:5NR", "summary": "This article displays the \"Price to sales forward\" financial metric for Nanobiotix SA, traded on Gettex under the symbol 5NR. The content primarily shows the financial data with a period, value, change, and change percentage. There is no additional textual analysis or commentary ", "url": "https://www.tradingview.com/symbols/GETTEX-5NR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T08:40:54", "published_display": "25 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform (NASDAQ:NBTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOSjktQmFmaUpRV1otTVF1dWFxblFrbGU5a2JIZU94dkdVZm1NWHJWVEVLd1FOX2R6b2RpeFpveDN5YkYwVkJIZEg4MVY1WUVXN19nc3BCXzJoTkJjdGhsWTFMMUZQejFDdjhxeFR2VEg1RGhoekxTbW9hWEotRTFzMWVJbTdfVzJuUDhRNWNTVXBtc1hYalB6S1ZUOTl0dXlpMnpzLWV4cXF0VEI5ZXpRNUIxRQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix SA (NBTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Nanobiotix SA (NBTX), detailing its current stock price, market capitalization, and various technical indicators. It presents a summary of buy, neutral, and sell signals derived from indicators like MACD, RSI, and moving averages, and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nbtx/technical", "source_name": "TradingKey", "published_at": "2026-06-24T12:39:33", "published_display": "24 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix (NBTX) Provides Update on Operational Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQYUlWMWVTdDdabXM4WGJJdHhsQkNGc0IydFF2TVFlZWFRNWdsM2JjUDF1NHQ1dDV4WUNIYThmTGM2dXg2RzVtZnljNXFUZVFjZlNjV2lCNVV1SmRoZlNONXpKNzkxTXFESW5YbmcycU9lNm9UUzY5ZmNrMHA4X1dyTFdIVVUxWmtfSVJSNS14MjZoVkdJTzZDN1ZJRlNkYUpXTVVqQWkwVlJhQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Drop 2% and Fall Below Short-Term Moving Averages", "summary": "Nanobiotix shares dropped by 2.17% to \u20ac29.74, falling below their short-term moving averages (MM20 and MM50) and erasing some early week gains. This decline extends a consolidation phase that began after the stock's historical high in mid-May, despite still showing a significant ", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-drop-2-and-fall-below-short-term-moving-averages/21249.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-19T14:51:00", "published_display": "19 Jun 2026 14:51", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix (ENXTPA:NANO) - Stock Analysis", "summary": "This article provides a detailed stock analysis of Nanobiotix (ENXTPA:NANO), a clinical-stage biotechnology company focused on cancer treatments. It covers the company's valuation, future growth prospects, past performance, financial health, and recent news, including a significa", "url": "https://simplywall.st/stocks/fr/pharmaceuticals-biotech/epa-nano/nanobiotix-shares", "source_name": "Simply Wall Street", "published_at": "2026-06-19T11:41:04", "published_display": "19 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Climb Over 3%, Leading Gains in the SBF 120", "summary": "Nanobiotix shares climbed over 3% in mid-morning trading, positioning the French biotech company as a top performer in the SBF 120. This rebound follows a period of consolidation after reaching a record high in mid-May and comes as the Parisian market also trends upward. The stoc", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-climb-over-3-leading-gains-in-the-sbf-120/21152.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-18T08:48:18", "published_display": "18 Jun 2026 08:48", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix SA (NBTX) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Nanobiotix SA (NBTX), including its current stock price, market cap, and a list of institutional shareholders. It highlights changes in shareholdings for various firms like Johnson & Johnson Innovation-JJDC, Inc., M", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nbtx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T16:40:03", "published_display": "17 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotech (NASDAQ:NBTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLU5ocFZoRVBXQ2hXUV9rbVFrQkhyaVVQVFBXVVFDdnQyQW5NQWk4TFFtQnFxa2wyVXRHdkdlVWRoZFg1ZFNrYWNnRndvdkVHd1FNVXplOUJsSWl0U3d0b0VTX3VWdThmWmZxRE9lMUtncURBVkNsWjE2SzBTU3FIVXhoTHl5RC02TXJjSjRxM3E4X1hxVl9BNGs5SXJlUnN1dW9fcFY3MGZ5X3NNdVE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Provides First Quarter 2026 Operational and Financial Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nanobiotix-provides-first-quarter-2026-203000820.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T20:30:00+00:00", "published_display": "02 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Joins Euronext Tech Leaders Index", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nanobiotix-joins-euronext-tech-leaders-072958672.html", "source_name": "MT Newswires", "published_at": "2026-06-02T07:29:58+00:00", "published_display": "02 Jun 2026 07:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "\u20ac86.1M raise extends Nanobiotix (NASDAQ: NBTX) cash runway into 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOZDFYSF9ySmNnRmg2cFVBblhZMy1vcWI5Yzl1R2NSbkhMWlp2aXFoRTJaakJweU9JM2h3dkdIemFOTndTMzhURjVOaVlrcWdCSW9leDU3S3l2QmdrdmF5ZjNVckxFRUZhaWVIVjdTQWd6Y0xMUzdoT1pqZWdyWkVhMy13MlVJMXpQVS10c0R5cUFhYUJXMVVkN0QtM3dtLWpZNDB5ZU5saU9pUDh6LWFF?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lung cancer trial shows responses in 6 of 7 patients on Nanobiotix drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNV21CZFJjM2JUM3lfTDNLNzNscVNNZXJZZWo4emw1UW5TTnVsSUVYUFZDemVxampaSjEtRjN5eUJpRjFGZFJWN3ZZNTlzV0NmOFE4WW5ESmVWd21QUW05aW1KekE2Q0h1VHYtcUU3UHBoOGxrbDllQmpWSFZrdWRPdDlobHlWU1hhbWJ3SFgyZnVIUmIzWGlCLTRLMXBfLWZUUU03alJESEtJeWowSmsxT3FDdXE2Z0UwZS1r?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix (NASDAQ: NBTX) joins Euronext Tech Leaders Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQLXh6NlFFNWZ1STh5eVZ5TEVfb0tnWTdxaVZQUFBWbGQ3Yk54Z214b2JKOVByWmFIZmEzcl9UUGJOX2lEMmpsMk1Wd1pkMEdiRzVISGdTQ1hDZFJYVktVZHQzMkxhUUdJT2p5QmdUX2ZEYnVFRkpiUlZVcnRZZGxfaGhIMVFJdmlnNC1LSUpidUdfODhzSXB2SFZtYkdJVjZXVmp4WTBUc2hFTEtscjlv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Joins the Euronext Tech Leaders Index", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nanobiotix-joins-euronext-tech-leaders-063000983.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T06:30:00+00:00", "published_display": "02 Jun 2026 06:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer nanotech firm Nanobiotix joins select Euronext Tech list", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQX0dfNm9OaFgxUHkzLWZtanZkQXVuXzBlTWtiUHNzazJlZUFIMkZXR0tsdjEyUlVGaExIaEtPd0c1ZmJhcWVhMTVtcE9YUlVoTjdiSkNxU2ppNWJPRFhtUGpHUXQ0MWRsZDRpLVozSEZWa2ZkRlFVOE1HRnNzaVdaYXlLZGpTVFZfYW04Zk9CR2tYNmpvbDl5TUZMMkVRUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOTmNsSHdMeExLYzFhQ19fcjVjbVpiZXhJWTZrbzB6LXNtNEt2WWIwSFY1LURyYVZZcDhpMVROdk1teHY5YVRGNUlQRVktd2dEOUI5WnVDZTl4ekZrUWpMZXVLWEVGRFRreHY2Z2YydWNRMjF4ZjBkTTZmbnF6aldSU21oNzROdnpweU1mMWxseHJvZHMzTFVzVHk4ZGpxU00?oc=5", "source_name": "Market source", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Closes $100 Million Global Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nanobiotix-closes-100-million-global-211846120.html", "source_name": "MT Newswires", "published_at": "2026-05-26T21:18:46+00:00", "published_display": "26 May 2026 21:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NANOBIOTIX Announces Closing of Global Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nanobiotix-announces-closing-global-offering-205900119.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T20:59:00+00:00", "published_display": "26 May 2026 20:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NANOBIOTIX Announces Full Exercise of Underwriters\u2019 Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nanobiotix-announces-full-exercise-underwriters-201500319.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T20:15:00+00:00", "published_display": "22 May 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer biotech Nanobiotix locks in $100M to support operations into 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPVm5xanpDVE5INTZGOTVjejRPRkZscVdhaHl2VUZuUGUyT3h2RFJoV0VMVU04X2JZczRITW5mTmZ5V0NDMDFWVXAteHZheVZFcFdfdEh2WjBKd1Y0Q0FZX3lFSXU0aEF0M3ZjNXcwRG9ZTDg4Y2RjdlE1RjhuSHhac3dQYThaeHRvSElfNXJiNkJjNGxvWno4MkktUGd2TTVsamtVLUtUVHhXRW9jeHFkNndDZzdyTzIxMkUyRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Prices $98.6 Million Global Follow-on Offering; Shares Fall", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nanobiotix-prices-98-6-million-153722929.html", "source_name": "MT Newswires", "published_at": "2026-05-21T15:37:22+00:00", "published_display": "21 May 2026 15:37", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNTmY0V0NhT21CenBTU19NdGVWWEJwUmltQWtJQ3M4b3JBako0ZHh2YkhLeG5ZVWZBclc5anhmMjhKYkRPZHdSSlZhaHlzUkIydnZsR0xhUHJRRFBLSVlMYjhSdm1OQ1N6cjExWFp6RTd2QTFzN0x6dllCbmlqTVg4MWp4bkttTVR5S2NKNmVlQmNUakx1Z1p4UHRtLTkzcWVhNW5BOXZGZUtXQ1BLbnc5TXdXYw?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix: Trading Halt on Euronext Paris for a Global Securities Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPdVRYbDdIT0pHU0tnbXBCMHJ4UldfVmFGb002czRlenlVSnpFQkxpRUp4NmZ3SFNGUGNzQ0VjVGtOckJLWmV1a29DZ2t0dUpySFk2eEJpRDhORkRYamhYcTZDY2VmUGR4a3pNRlRfUjJXVUZPVFBBS3piWlp1cnloZGV1S05BQU9VYjFBVHJJb1QyT2V6VTZQelE5dGJENkdOWDJyWWdYZGFzbTVrbVVsMDdTYmRUcU5aR2pVMXdRVTYxYXJJV3RueUhVYXBCZw?oc=5", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix (NBTX) Sees a Significant Decline in Share Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNMVpObTVCNVM3WGpUZlpWTl96M3dIeGI4TmpBUnVuQzlqcXJQSjRZb21ZS0RKR3R5VEJTNTY2cFkxXzg1QVgtaElWVDktS1p2cWxEd2Y0WlVGN0ZHVElsQTFla1BJczQ1ZlFpZHFxa2FCOVNSdThHemN3Slh6YmU5c0tzaU4yeHlwUzNUdlpwS1hXblJFNDVfR2xBa0xrSHJTT043SWNGeTJHUDViN252MGpCY2trUnpvUVF5WnNPbHB0Zw?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer biotech Nanobiotix pauses Paris trading for U.S. share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPOEFmNTk3T0tfX1pnaV9FTF9lbkdKV2hZdEJxUXdDNnlXU091d3pVcTJxazY0RXhFaXN2RUR1SnVQckJnd3JuOUh3elllLV82eFdNWDdteUJ0eFdBWFNmaFZ0N3AwMWgwVW52MFNDSmY5WmNnb1dmb1loTGVBaUVrelRjdHBDQ21XbFRNcnlRd0p1V3l5UWxycTVaMVRmTnhHMHhqLTNxejhZb0pTQmc3MkI1RWU3MlF5c0ZoMzlR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix (NBTX) Initiates \u20ac75 Million Global Follow-On Offerin", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxPMW1FdG55SFVJRjIxYjlGR3hXTE9WR0lyS1NGSnJlb0owQUFfSFI3MTV4YkgzQ0hJTDhSaE9TT3dfZkc2aEtac2NzSGYyMy1TVElpZWdIVmJoMzkwdXBCQXU0eGo3Y3RCbEtqWlJLU2ZkTi1uN1JqS1UwN29BT3JHSFFjWEVybXAtS3pDd0VBaU5xYlFEdF9DN2xwZjdIS2VvYUVIa2lhR05fTE9kUmlhdl8wOHQwVTc2akthY3Zfb0ZSa2YzZVotU2F4RzR6QnhhS3hFdV9Pc3E2OVhuZmxVYzF6ZG5reW00NU1rWmkzX2E2QQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPNVNpS1FVUWZQQmV5d19RQnY5U0Jqc3F5X1dBSkJfVERLQ0xab01QZ08tSS0tMXpQUUVFY0x1cFNMTEtJd1AyQUNGbUpkeWhtTVBFbVk0VVU4bDdYTlNBVWNwZnozWDZNOTlYLVRkMC1TMlhFOGhVZWliQVpIYVg5RkVGLVdsNGczWGtvamx2RDRfLXE0cmRqd1U5M1V1Tk5ZM013cGxmOFk1OVNE?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Announces Launch of Global Follow-On Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQcU1PcXZUa0xkRnVKZDA0bGJib3pCV1lkUFlVdVplUnhSeEFTUExodmlwaVRNZW9tSzRpX3hGU3BtVm9LQWFyeTNrVWFob1N4THdhdHREdENXM0dBVjR3emVXcGhCMWRidkZBQld4NElkR1lEejlCUGRoYXJINFhMamhEOGktNGg3SjBjUW5kaHNJQnNabmRxclRxRnNJTVBjV1B0VmhZbVZQNjky?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Nanobiotix Shares Soar Nearly 5%, Targeting Resistance at \u20ac36.20", "summary": "Nanobiotix shares gained almost 5%, reaching \u20ac32.76, making it one of the strongest performers in the SBF 120. This rebound follows a week of consolidation, pushing the stock closer to its MM20 moving average. The company's annual performance remains exceptionally strong, with a ", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-soar-nearly-5-targeting-resistance-at-eur36-20/22844.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-21T09:40:49", "published_display": "21 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Soar by 4.5%, Leading the SBF 120", "summary": "Nanobiotix shares gained 4.25% to \u20ac34.36, leading the SBF 120 and moving above its short-term moving averages. The company's annual performance remains strong, driven by clinical advancements of its candidate JNJ-1900 (NBTXR3) and encouraging phase 2 results. The stock's current ", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-soar-by-4-5-leading-the-sbf-120/22797.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-20T12:39:18", "published_display": "20 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Drop Nearly 3% Yet Maintain an Annual Gain of 692%", "summary": "Nanobiotix stock experienced a nearly 3% drop on Wednesday, placing it among the biggest declines in the SBF 120 index. This downturn is attributed to profit-taking following strong gains, despite the company still boasting an impressive annual performance of nearly 692%. The sto", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-drop-nearly-3-yet-maintain-an-annual-gain-of-692/22652.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-15T12:15:00", "published_display": "15 Jul 2026 12:15", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nanobiotix SA \u2013 EURONEXT:NANO", "summary": "The article provides a financial overview of Nanobiotix SA (EURONEXT: NANO), specifically focusing on its forward price-to-sales ratio. It indicates that the market is closed, and there are no current trades for the stock, with the content being a snapshot from TradingView's fina", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T00:12:52", "published_display": "15 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix S.A. Stock 12\u2011Month Price Target Raised to $54.34, Implies 40% Upside", "summary": "Nanobiotix S.A. (NANO) has seen its average 12-month price target raised to $54.34 by 8 analysts, up from $52.3, suggesting a 40% potential upside from its Jul. 9 closing price. The consensus rating among 9 analysts remains a \"Buy,\" with 8 recommending Buy and 1 recommending Hold", "url": "https://www.tradingview.com/news/tradingview:df5c7bff01086:0-nanobiotix-s-a-stock-12-month-price-target-raised-to-54-34-implies-40-upside/", "source_name": "TradingView", "published_at": "2026-07-10T13:39:53", "published_display": "10 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Nanobiotix SA \u2013 EURONEXT:NANO", "summary": "The article provides financial information for Nanobiotix SA (Euronext: NANO), specifically focusing on its enterprise value to EBIT forward. It indicates basic financial data for the company on the TradingView platform, noting that the market was closed at the time of publicatio", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T09:40:50", "published_display": "10 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Soar Over 5%, Landing on the SBF 120 Podium", "summary": "Nanobiotix shares surged over 5% in early trading, propelled by a \"buy\" rating and a \u20ac56 target price from Portzamparc, representing a potential upside of over 55%. The biotech stock broke through its resistance at \u20ac35.18, signaling a bullish resumption, and has seen a 668% gain ", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-soar-over-5-landing-on-the-sbf-120-podium/22502.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-10T09:39:53", "published_display": "10 Jul 2026 09:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nanobiotix SA \u2013 MUN:5NR", "summary": "This article provides financial information for Nanobiotix SA (MUN:5NR), specifically focusing on its price-to-sales forward metric. It appears to be a stub or a data point from a financial platform like TradingView, with no further detailed analysis provided. The content highlig", "url": "https://www.tradingview.com/symbols/MUN-5NR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T03:39:23", "published_display": "10 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Confirm Their Rebound with a +625% Yearly Increase", "summary": "Nanobiotix shares have confirmed their rebound, showing a +625% increase over the past year. The French biotech company's stock is up 2.03% to \u20ac34.10, trading above its short-term moving averages and indicating continued bullish momentum with an RSI of 57. This growth is supporte", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-confirm-their-rebound-with-a-625-yearly-increase/22463.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-09T15:11:12", "published_display": "09 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Nanobiotix S.A. (NBTX)", "summary": "This article examines the historical performance of Nanobiotix S.A. (NBTX) stock, illustrating how a $1,000 investment would have grown over various periods. It details the company's focus on physics-based therapeutic approaches, particularly its oncology product candidate JNJ-19", "url": "https://www.stocktitan.net/tools/stock-return-calculator/NBTX", "source_name": "Stock Titan", "published_at": "2026-07-04T05:09:27", "published_display": "04 Jul 2026 05:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NBTX - Nanobiotix ADR Dividends", "summary": "This article provides detailed financial data and performance metrics for Nanobiotix ADR (NBTX). It covers key financial figures such as market cap, income, sales, and various ratios, along with stock performance over different periods. The data indicates strong past performance ", "url": "https://finviz.com/stock?t=NBTX&ty=dv&ta=1&p=d", "source_name": "Finviz", "published_at": "2026-07-04T01:39:50", "published_display": "04 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Soar 5% and Aim for Record Highs", "summary": "Nanobiotix shares have surged by 5% and are targeting new record highs, becoming a top performer on the Paris index after a period of consolidation. The company's strong performance is supported by technical indicators, significant advances in clinical studies for JNJ-1900, the s", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-soar-5-and-aim-for-record-highs/22051.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-07-03T17:43:00", "published_display": "03 Jul 2026 17:43", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Up 3.73%, Targeting the 50-Day Moving Average of \u20ac32.70", "summary": "Nanobiotix shares have risen by 3.73% to \u20ac32.28, nearing their 50-day moving average of \u20ac32.70. This rebound follows a period of consolidation after an annual rally, positioning the stock among the top performers on the SBF 120. Despite a recent increase in bearish pressure, the ", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-up-3-73-targeting-the-50-day-moving-average-of-eur32-70/21780.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-30T10:10:04", "published_display": "30 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Decline by 1.5% and Remain Under Pressure Following May Record", "summary": "Nanobiotix shares have fallen by 1.5% and continue to face pressure in a declining Parisian market, consolidating after hitting a record high in mid-May. The stock is currently trading near its 20-day moving average, with bearish bets increasing, although the total short position", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-decline-by-1-5-and-remain-under-pressure-following-may-record/21722.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-29T12:41:20", "published_display": "29 Jun 2026 12:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Nanobiotix SA \u2013 EURONEXT:NANO", "summary": "This article provides access to the enterprise value to EBITDA forward for Nanobiotix SA (EURONEXT:NANO). It primarily functions as a financial data page on TradingView, indicating that specific financial metrics for the company are available for users to view. The content points", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:09:56", "published_display": "27 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Nanobiotix SA \u2013 AQUISEU:NANOP", "summary": "This article provides financial data for Nanobiotix SA (NANOP), specifically its enterprise value to EBITDA forward. It details that the market for this stock is currently closed with no trades recorded. The information is presented by TradingView, sourcing data from ICE Data Ser", "url": "https://www.tradingview.com/symbols/AQUISEU-NANOP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:33", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NANO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an in-depth analysis of Nanobiotix SA (NANO) stock, including its current price, analyst forecasts, historical performance, and financial data. It highlights the company's recent stock increase over the last year, future earnings and revenue expectations, an", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T01:06:36", "published_display": "27 Jun 2026 01:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Nanobiotix SA \u2013 EURONEXT:NANO", "summary": "The article focuses on financial data for Nanobiotix SA (NANO) on Euronext, specifically its \"Price to earnings forward\" metric. It appears to be a financial data page from TradingView, providing an overview of the company's financial performance, news, and community discussions.", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:05:36", "published_display": "27 Jun 2026 01:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NBTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target and analyst ratings for Nanobiotix S.A. (NBTX) for 2027. Nine analysts offer a 1-year price forecast with an average target of 49.59, though maximum and minimum estimates are not provided. The content also notes that 10 analysts have given sto", "url": "https://www.tradingview.com/symbols/BOATS-NBTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:36", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Nanobiotix SA \u2013 EURONEXT:NANO", "summary": "This article displays the \"Price to book forward\" financial metric for Nanobiotix SA (Euronext: NANO) as found on TradingView. It indicates that no trades were recorded and the market was closed at the time of access. The data is provided by ICE Data Services and FactSet, with SE", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:10:09", "published_display": "26 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Fall by 2.5%, in the Red on the SBF 120", "summary": "Nanobiotix shares have fallen by 2.5% on the SBF 120, extending a consolidation phase due to renewed risk aversion from U.S. inflation figures. Despite a monthly decline of over 20%, the stock's annual performance remains strong, boasting over 640% growth. The biotech is also aff", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-fall-by-2-5-in-the-red-on-the-sbf-120/21618.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-26T10:38:09", "published_display": "26 Jun 2026 10:38", "sentiment": "negative", "sentiment_pct": 29, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix SA Actuals & Estimates (EURONEXT:NANO)", "summary": "This article provides an overview of Nanobiotix SA (NANO) stock, including its current price, performance trends, and analyst forecasts. It details financial actuals and estimates for income, balance sheet, and cash flow, alongside key metrics like market capitalization, EBITDA, ", "url": "https://www.tradingview.com/symbols/EURONEXT-NANO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:09:36", "published_display": "25 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Nanobiotix SA \u2013 GETTEX:5NR", "summary": "This article provides financial information for Nanobiotix SA (GETTEX:5NR), specifically focusing on its price to book forward metric. It appears to be a financial data snippet from TradingView, offering a quick look at the company's valuation under the \"Financials\" section. The ", "url": "https://www.tradingview.com/symbols/GETTEX-5NR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T15:09:36", "published_display": "25 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Fall by 2.5%, Down Nearly 19% Over the Month", "summary": "Nanobiotix shares have fallen by 2.5% today and nearly 19% over the past month, trading at \u20ac29.50. This decline occurs despite a positive trend in the broader Parisian market and successful progress in the company's clinical trials and cash reserve reinforcement. The stock's perf", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-fall-by-2-5-down-nearly-19-over-the-month/21551.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-25T09:40:54", "published_display": "25 Jun 2026 09:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Nanobiotix SA \u2013 GETTEX:5NR", "summary": "This article displays the \"Price to sales forward\" financial metric for Nanobiotix SA, traded on Gettex under the symbol 5NR. The content primarily shows the financial data with a period, value, change, and change percentage. There is no additional textual analysis or commentary ", "url": "https://www.tradingview.com/symbols/GETTEX-5NR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T08:40:54", "published_display": "25 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform (NASDAQ:NBTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOSjktQmFmaUpRV1otTVF1dWFxblFrbGU5a2JIZU94dkdVZm1NWHJWVEVLd1FOX2R6b2RpeFpveDN5YkYwVkJIZEg4MVY1WUVXN19nc3BCXzJoTkJjdGhsWTFMMUZQejFDdjhxeFR2VEg1RGhoekxTbW9hWEotRTFzMWVJbTdfVzJuUDhRNWNTVXBtc1hYalB6S1ZUOTl0dXlpMnpzLWV4cXF0VEI5ZXpRNUIxRQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix SA (NBTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Nanobiotix SA (NBTX), detailing its current stock price, market capitalization, and various technical indicators. It presents a summary of buy, neutral, and sell signals derived from indicators like MACD, RSI, and moving averages, and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nbtx/technical", "source_name": "TradingKey", "published_at": "2026-06-24T12:39:33", "published_display": "24 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix (NBTX) Provides Update on Operational Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQYUlWMWVTdDdabXM4WGJJdHhsQkNGc0IydFF2TVFlZWFRNWdsM2JjUDF1NHQ1dDV4WUNIYThmTGM2dXg2RzVtZnljNXFUZVFjZlNjV2lCNVV1SmRoZlNONXpKNzkxTXFESW5YbmcycU9lNm9UUzY5ZmNrMHA4X1dyTFdIVVUxWmtfSVJSNS14MjZoVkdJTzZDN1ZJRlNkYUpXTVVqQWkwVlJhQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Drop 2% and Fall Below Short-Term Moving Averages", "summary": "Nanobiotix shares dropped by 2.17% to \u20ac29.74, falling below their short-term moving averages (MM20 and MM50) and erasing some early week gains. This decline extends a consolidation phase that began after the stock's historical high in mid-May, despite still showing a significant ", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-drop-2-and-fall-below-short-term-moving-averages/21249.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-19T14:51:00", "published_display": "19 Jun 2026 14:51", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix (ENXTPA:NANO) - Stock Analysis", "summary": "This article provides a detailed stock analysis of Nanobiotix (ENXTPA:NANO), a clinical-stage biotechnology company focused on cancer treatments. It covers the company's valuation, future growth prospects, past performance, financial health, and recent news, including a significa", "url": "https://simplywall.st/stocks/fr/pharmaceuticals-biotech/epa-nano/nanobiotix-shares", "source_name": "Simply Wall Street", "published_at": "2026-06-19T11:41:04", "published_display": "19 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Shares Climb Over 3%, Leading Gains in the SBF 120", "summary": "Nanobiotix shares climbed over 3% in mid-morning trading, positioning the French biotech company as a top performer in the SBF 120. This rebound follows a period of consolidation after reaching a record high in mid-May and comes as the Parisian market also trends upward. The stoc", "url": "https://www.ideal-investisseur.fr/en/stock-news/nanobiotix-shares-climb-over-3-leading-gains-in-the-sbf-120/21152.html", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-06-18T08:48:18", "published_display": "18 Jun 2026 08:48", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix SA (NBTX) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Nanobiotix SA (NBTX), including its current stock price, market cap, and a list of institutional shareholders. It highlights changes in shareholdings for various firms like Johnson & Johnson Innovation-JJDC, Inc., M", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nbtx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T16:40:03", "published_display": "17 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotech (NASDAQ:NBTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLU5ocFZoRVBXQ2hXUV9rbVFrQkhyaVVQVFBXVVFDdnQyQW5NQWk4TFFtQnFxa2wyVXRHdkdlVWRoZFg1ZFNrYWNnRndvdkVHd1FNVXplOUJsSWl0U3d0b0VTX3VWdThmWmZxRE9lMUtncURBVkNsWjE2SzBTU3FIVXhoTHl5RC02TXJjSjRxM3E4X1hxVl9BNGs5SXJlUnN1dW9fcFY3MGZ5X3NNdVE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Provides First Quarter 2026 Operational and Financial Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nanobiotix-provides-first-quarter-2026-203000820.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T20:30:00+00:00", "published_display": "02 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Joins Euronext Tech Leaders Index", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nanobiotix-joins-euronext-tech-leaders-072958672.html", "source_name": "MT Newswires", "published_at": "2026-06-02T07:29:58+00:00", "published_display": "02 Jun 2026 07:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "\u20ac86.1M raise extends Nanobiotix (NASDAQ: NBTX) cash runway into 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOZDFYSF9ySmNnRmg2cFVBblhZMy1vcWI5Yzl1R2NSbkhMWlp2aXFoRTJaakJweU9JM2h3dkdIemFOTndTMzhURjVOaVlrcWdCSW9leDU3S3l2QmdrdmF5ZjNVckxFRUZhaWVIVjdTQWd6Y0xMUzdoT1pqZWdyWkVhMy13MlVJMXpQVS10c0R5cUFhYUJXMVVkN0QtM3dtLWpZNDB5ZU5saU9pUDh6LWFF?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lung cancer trial shows responses in 6 of 7 patients on Nanobiotix drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNV21CZFJjM2JUM3lfTDNLNzNscVNNZXJZZWo4emw1UW5TTnVsSUVYUFZDemVxampaSjEtRjN5eUJpRjFGZFJWN3ZZNTlzV0NmOFE4WW5ESmVWd21QUW05aW1KekE2Q0h1VHYtcUU3UHBoOGxrbDllQmpWSFZrdWRPdDlobHlWU1hhbWJ3SFgyZnVIUmIzWGlCLTRLMXBfLWZUUU03alJESEtJeWowSmsxT3FDdXE2Z0UwZS1r?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix (NASDAQ: NBTX) joins Euronext Tech Leaders Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQLXh6NlFFNWZ1STh5eVZ5TEVfb0tnWTdxaVZQUFBWbGQ3Yk54Z214b2JKOVByWmFIZmEzcl9UUGJOX2lEMmpsMk1Wd1pkMEdiRzVISGdTQ1hDZFJYVktVZHQzMkxhUUdJT2p5QmdUX2ZEYnVFRkpiUlZVcnRZZGxfaGhIMVFJdmlnNC1LSUpidUdfODhzSXB2SFZtYkdJVjZXVmp4WTBUc2hFTEtscjlv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Joins the Euronext Tech Leaders Index", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nanobiotix-joins-euronext-tech-leaders-063000983.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T06:30:00+00:00", "published_display": "02 Jun 2026 06:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer nanotech firm Nanobiotix joins select Euronext Tech list", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQX0dfNm9OaFgxUHkzLWZtanZkQXVuXzBlTWtiUHNzazJlZUFIMkZXR0tsdjEyUlVGaExIaEtPd0c1ZmJhcWVhMTVtcE9YUlVoTjdiSkNxU2ppNWJPRFhtUGpHUXQ0MWRsZDRpLVozSEZWa2ZkRlFVOE1HRnNzaVdaYXlLZGpTVFZfYW04Zk9CR2tYNmpvbDl5TUZMMkVRUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOTmNsSHdMeExLYzFhQ19fcjVjbVpiZXhJWTZrbzB6LXNtNEt2WWIwSFY1LURyYVZZcDhpMVROdk1teHY5YVRGNUlQRVktd2dEOUI5WnVDZTl4ekZrUWpMZXVLWEVGRFRreHY2Z2YydWNRMjF4ZjBkTTZmbnF6aldSU21oNzROdnpweU1mMWxseHJvZHMzTFVzVHk4ZGpxU00?oc=5", "source_name": "Market source", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Closes $100 Million Global Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nanobiotix-closes-100-million-global-211846120.html", "source_name": "MT Newswires", "published_at": "2026-05-26T21:18:46+00:00", "published_display": "26 May 2026 21:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NANOBIOTIX Announces Closing of Global Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nanobiotix-announces-closing-global-offering-205900119.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T20:59:00+00:00", "published_display": "26 May 2026 20:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NANOBIOTIX Announces Full Exercise of Underwriters\u2019 Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/nanobiotix-announces-full-exercise-underwriters-201500319.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T20:15:00+00:00", "published_display": "22 May 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer biotech Nanobiotix locks in $100M to support operations into 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPVm5xanpDVE5INTZGOTVjejRPRkZscVdhaHl2VUZuUGUyT3h2RFJoV0VMVU04X2JZczRITW5mTmZ5V0NDMDFWVXAteHZheVZFcFdfdEh2WjBKd1Y0Q0FZX3lFSXU0aEF0M3ZjNXcwRG9ZTDg4Y2RjdlE1RjhuSHhac3dQYThaeHRvSElfNXJiNkJjNGxvWno4MkktUGd2TTVsamtVLUtUVHhXRW9jeHFkNndDZzdyTzIxMkUyRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Prices $98.6 Million Global Follow-on Offering; Shares Fall", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nanobiotix-prices-98-6-million-153722929.html", "source_name": "MT Newswires", "published_at": "2026-05-21T15:37:22+00:00", "published_display": "21 May 2026 15:37", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNTmY0V0NhT21CenBTU19NdGVWWEJwUmltQWtJQ3M4b3JBako0ZHh2YkhLeG5ZVWZBclc5anhmMjhKYkRPZHdSSlZhaHlzUkIydnZsR0xhUHJRRFBLSVlMYjhSdm1OQ1N6cjExWFp6RTd2QTFzN0x6dllCbmlqTVg4MWp4bkttTVR5S2NKNmVlQmNUakx1Z1p4UHRtLTkzcWVhNW5BOXZGZUtXQ1BLbnc5TXdXYw?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix: Trading Halt on Euronext Paris for a Global Securities Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPdVRYbDdIT0pHU0tnbXBCMHJ4UldfVmFGb002czRlenlVSnpFQkxpRUp4NmZ3SFNGUGNzQ0VjVGtOckJLWmV1a29DZ2t0dUpySFk2eEJpRDhORkRYamhYcTZDY2VmUGR4a3pNRlRfUjJXVUZPVFBBS3piWlp1cnloZGV1S05BQU9VYjFBVHJJb1QyT2V6VTZQelE5dGJENkdOWDJyWWdYZGFzbTVrbVVsMDdTYmRUcU5aR2pVMXdRVTYxYXJJV3RueUhVYXBCZw?oc=5", "source_name": "Id\u00e9al Investisseur", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix (NBTX) Sees a Significant Decline in Share Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNMVpObTVCNVM3WGpUZlpWTl96M3dIeGI4TmpBUnVuQzlqcXJQSjRZb21ZS0RKR3R5VEJTNTY2cFkxXzg1QVgtaElWVDktS1p2cWxEd2Y0WlVGN0ZHVElsQTFla1BJczQ1ZlFpZHFxa2FCOVNSdThHemN3Slh6YmU5c0tzaU4yeHlwUzNUdlpwS1hXblJFNDVfR2xBa0xrSHJTT043SWNGeTJHUDViN252MGpCY2trUnpvUVF5WnNPbHB0Zw?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer biotech Nanobiotix pauses Paris trading for U.S. share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPOEFmNTk3T0tfX1pnaV9FTF9lbkdKV2hZdEJxUXdDNnlXU091d3pVcTJxazY0RXhFaXN2RUR1SnVQckJnd3JuOUh3elllLV82eFdNWDdteUJ0eFdBWFNmaFZ0N3AwMWgwVW52MFNDSmY5WmNnb1dmb1loTGVBaUVrelRjdHBDQ21XbFRNcnlRd0p1V3l5UWxycTVaMVRmTnhHMHhqLTNxejhZb0pTQmc3MkI1RWU3MlF5c0ZoMzlR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix (NBTX) Initiates \u20ac75 Million Global Follow-On Offerin", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxPMW1FdG55SFVJRjIxYjlGR3hXTE9WR0lyS1NGSnJlb0owQUFfSFI3MTV4YkgzQ0hJTDhSaE9TT3dfZkc2aEtac2NzSGYyMy1TVElpZWdIVmJoMzkwdXBCQXU0eGo3Y3RCbEtqWlJLU2ZkTi1uN1JqS1UwN29BT3JHSFFjWEVybXAtS3pDd0VBaU5xYlFEdF9DN2xwZjdIS2VvYUVIa2lhR05fTE9kUmlhdl8wOHQwVTc2akthY3Zfb0ZSa2YzZVotU2F4RzR6QnhhS3hFdV9Pc3E2OVhuZmxVYzF6ZG5reW00NU1rWmkzX2E2QQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPNVNpS1FVUWZQQmV5d19RQnY5U0Jqc3F5X1dBSkJfVERLQ0xab01QZ08tSS0tMXpQUUVFY0x1cFNMTEtJd1AyQUNGbUpkeWhtTVBFbVk0VVU4bDdYTlNBVWNwZnozWDZNOTlYLVRkMC1TMlhFOGhVZWliQVpIYVg5RkVGLVdsNGczWGtvamx2RDRfLXE0cmRqd1U5M1V1Tk5ZM013cGxmOFk1OVNE?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nanobiotix Announces Launch of Global Follow-On Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQcU1PcXZUa0xkRnVKZDA0bGJib3pCV1lkUFlVdVplUnhSeEFTUExodmlwaVRNZW9tSzRpX3hGU3BtVm9LQWFyeTNrVWFob1N4THdhdHREdENXM0dBVjR3emVXcGhCMWRidkZBQld4NElkR1lEejlCUGRoYXJINFhMamhEOGktNGg3SjBjUW5kaHNJQnNabmRxclRxRnNJTVBjV1B0VmhZbVZQNjky?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 107, "total_relevant": 68, "sentiment_summary": {"positive": 15, "negative": 8, "neutral": 45, "score": 53, "total": 68, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 27.45, "count": 48}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 37.79, "latest_week": "2026-07-17", "one_week_move": -5.7, "four_week_move": 4.2, "twelve_week_move": 12.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.186208, "market_dynamics_buy_signal": false, "relative_strength": 38.013469, "fair_value_gap": 213.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.9954, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.7% over one week, +4.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Id\u00e9al Investisseur", "count": 13}, {"label": "TradingView", "count": 13}, {"label": "Market source", "count": 10}, {"label": "Stock Titan", "count": 7}, {"label": "GlobeNewswire", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "Seeking Alpha", "count": 2}, {"label": "TradingKey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 59}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 48}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 2}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "59", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-5.7% over one week, +4.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Nanobiotix Shares Soar Nearly 5%, Targeting Resistance at \u20ac36.20"}], "updated_at": "2026-07-22T12:44:33.679096+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}